ASH 2018 | Predicting IMiD sensitivity in myeloma
Rafael Fonseca
• 1 Dec 2018
Rafael Fonseca, MD, of the Mayo Clinic, Phoenix, AZ, discusses research currently being performed to allow for the prediction of individual multiple myeloma patient’s responses to drugs, particularly lenalidomide and pomalidomide. Dr Fonseca speaks at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, and explains how flow cytometry assays that measure oxidative stress relief were used in the study to predict sensitivity to immunomodulatory imide drugs (IMIDs).
